287 related articles for article (PubMed ID: 32311398)
1. TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial.
Forman SB; Pariser DM; Poulin Y; Vincent MS; Gilbert SA; Kieras EM; Qiu R; Yu D; Papacharalambous J; Tehlirian C; Peeva E
J Invest Dermatol; 2020 Dec; 140(12):2359-2370.e5. PubMed ID: 32311398
[TBL] [Abstract][Full Text] [Related]
2. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
Banfield C; Scaramozza M; Zhang W; Kieras E; Page KM; Fensome A; Vincent M; Dowty ME; Goteti K; Winkle PJ; Peeva E
J Clin Pharmacol; 2018 Apr; 58(4):434-447. PubMed ID: 29266308
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study.
Schmieder GJ; Draelos ZD; Pariser DM; Banfield C; Cox L; Hodge M; Kieras E; Parsons-Rich D; Menon S; Salganik M; Page K; Peeva E
Br J Dermatol; 2018 Jul; 179(1):54-62. PubMed ID: 28949012
[TBL] [Abstract][Full Text] [Related]
4. Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.
Page KM; Suarez-Farinas M; Suprun M; Zhang W; Garcet S; Fuentes-Duculan J; Li X; Scaramozza M; Kieras E; Banfield C; Clark JD; Fensome A; Krueger JG; Peeva E
J Invest Dermatol; 2020 Aug; 140(8):1546-1555.e4. PubMed ID: 31972249
[TBL] [Abstract][Full Text] [Related]
5. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
Papp KA; Bissonnette R; Gooderham M; Feldman SR; Iversen L; Soung J; Draelos Z; Mamolo C; Purohit V; Wang C; Ports WC
BMC Dermatol; 2016 Oct; 16(1):15. PubMed ID: 27716172
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study.
Peeva E; Hodge MR; Kieras E; Vazquez ML; Goteti K; Tarabar SG; Alvey CW; Banfield C
Br J Clin Pharmacol; 2018 Aug; 84(8):1776-1788. PubMed ID: 29672897
[TBL] [Abstract][Full Text] [Related]
7. Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study.
Tehlirian C; Singh RSP; Pradhan V; Roberts ES; Tarabar S; Peeva E; Vincent MS; Gale JD
J Am Acad Dermatol; 2022 Aug; 87(2):333-342. PubMed ID: 35398218
[TBL] [Abstract][Full Text] [Related]
8. Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study.
Singh RSP; Pradhan V; Roberts ES; Scaramozza M; Kieras E; Gale JD; Peeva E; Vincent MS; Banerjee A; Fensome A; Dowty ME; Winkle P; Tehlirian C
Clin Transl Sci; 2021 Mar; 14(2):671-682. PubMed ID: 33290616
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study.
Tehlirian C; Peeva E; Kieras E; Scaramozza M; Roberts ES; Singh RSP; Pradhan V; Banerjee A; Garcet S; Xi L; Gale JD; Vincent MS; Krueger J
Lancet Rheumatol; 2021 Mar; 3(3):e204-e213. PubMed ID: 38279383
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
Papp KA; Menter MA; Abe M; Elewski B; Feldman SR; Gottlieb AB; Langley R; Luger T; Thaci D; Buonanno M; Gupta P; Proulx J; Lan S; Wolk R;
Br J Dermatol; 2015 Oct; 173(4):949-61. PubMed ID: 26149717
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
Papp KA; Menter A; Strober B; Langley RG; Buonanno M; Wolk R; Gupta P; Krishnaswami S; Tan H; Harness JA
Br J Dermatol; 2012 Sep; 167(3):668-77. PubMed ID: 22924949
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
Gooderham MJ; Forman SB; Bissonnette R; Beebe JS; Zhang W; Banfield C; Zhu L; Papacharalambous J; Vincent MS; Peeva E
JAMA Dermatol; 2019 Dec; 155(12):1371-1379. PubMed ID: 31577341
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Simpson EL; Sinclair R; Forman S; Wollenberg A; Aschoff R; Cork M; Bieber T; Thyssen JP; Yosipovitch G; Flohr C; Magnolo N; Maari C; Feeney C; Biswas P; Tatulych S; Valdez H; Rojo R
Lancet; 2020 Jul; 396(10246):255-266. PubMed ID: 32711801
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.
Papp KA; Menter MA; Raman M; Disch D; Schlichting DE; Gaich C; Macias W; Zhang X; Janes JM
Br J Dermatol; 2016 Jun; 174(6):1266-76. PubMed ID: 26800231
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.
Ports WC; Khan S; Lan S; Lamba M; Bolduc C; Bissonnette R; Papp K
Br J Dermatol; 2013 Jul; 169(1):137-45. PubMed ID: 23387374
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
Papp KA; Krueger JG; Feldman SR; Langley RG; Thaci D; Torii H; Tyring S; Wolk R; Gardner A; Mebus C; Tan H; Luo Y; Gupta P; Mallbris L; Tatulych S
J Am Acad Dermatol; 2016 May; 74(5):841-50. PubMed ID: 26899199
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.
Papp K; Gordon K; Thaçi D; Morita A; Gooderham M; Foley P; Girgis IG; Kundu S; Banerjee S
N Engl J Med; 2018 Oct; 379(14):1313-1321. PubMed ID: 30205746
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial.
Imafuku S; Tada Y; Hippeli L; Banerjee S; Morita A; Ohtsuki M
J Dermatol; 2023 May; 50(5):588-595. PubMed ID: 36882942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
